Biosimilars: Is The Game About To Change In Europe?
Executive Summary
Seven years since the first biosimilar hit the European market, these almost-copies have clearly disappointed. Now, though, momentum is building. Attitudes and regulations are slowly changing as cost-pressures continue – with implications for the U.S. And they’re doing so just as regulators review biosimilar Remicade, the first of a potentially far more lucrative set of copycat biologics.
You may also be interested in...
Celltrion CEO Cites Pfizer, J&J and Sanofi As Potential Buyers For Biosimilars Business
Although Korea’s Celltrion is not in takeover talks yet, CEO Seo Jung-jin named potential buyers after announcing he would sell his stake in the company he founded. Celltrion is expecting approval shortly in Europe for a biosimilar of J&J’s Remicade.
Where Are The Biosimilars?
An abbreviated pathway for follow-on biologics was one of the biggest issues for biotech investors in the legislative debate over health care reform. Two years after enactment, FDA is still waiting for the first application.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”